Oncopeptides AB Total Assets
Oncopeptides AB total assets. Based on the latest financial reports, Oncopeptides AB (ONCO) holds total assets worth Skr134.84 Million SEK (≈ $14.51 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Oncopeptides AB worth for the company's overall valuation and market capitalisation.
Total Assets of Oncopeptides AB (2014–2025)
Total assets of Oncopeptides AB from 2014 to 2025. This chart illustrates how Oncopeptides AB's total assets have evolved over time, based on quarterly financial data. See ONCO stock price and chart for real-time trading data and today's change.
Oncopeptides AB - Asset Composition Analysis
Oncopeptides AB Total Assets Breakdown (December 2025)
Oncopeptides AB total assets breakdown as of December 2025. Oncopeptides AB's total assets of Skr134.84 Million consist of 86.9% current assets and 13.1% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 61.0% |
| Accounts Receivable | Skr26.66 Million | 19.8% |
| Inventory | Skr8.24 Million | 6.1% |
| Property, Plant & Equipment | Skr17.68 Million | 13.1% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Oncopeptides AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Oncopeptides AB working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oncopeptides AB's current assets represent 86.9% of total assets in 2025, a decrease from 98.6% in 2014.
- Cash Position: Cash and equivalents constituted 61.0% of total assets in 2025, down from 91.2% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 19.8% of total assets.
Oncopeptides AB Competitors by Total Assets
Key competitors of Oncopeptides AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Oncopeptides AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.63 | 4.23 | 1.55 |
| Quick Ratio | 2.45 | 4.14 | 1.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr72.66 Million | Skr165.73 Million | Skr188.77 Million |
Oncopeptides AB - Advanced Valuation Insights
This section examines the relationship between Oncopeptides AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 72.93 |
| Latest Market Cap to Assets Ratio | 0.52 |
| Asset Growth Rate (YoY) | -44.8% |
| Total Assets | Skr134.84 Million |
| Market Capitalization | $69.81 Million USD |
Valuation Analysis
Below Book Valuation: The market values Oncopeptides AB's assets below their book value (0.52x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Oncopeptides AB's assets decreased by 44.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Oncopeptides AB (2014–2025)
The table below shows the annual total assets of Oncopeptides AB from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr134.84 Million ≈ $14.51 Million |
-44.78% |
| 2024-12-31 | Skr244.19 Million ≈ $26.28 Million |
+2.44% |
| 2023-12-31 | Skr238.38 Million ≈ $25.65 Million |
-38.14% |
| 2022-12-31 | Skr385.32 Million ≈ $41.47 Million |
-12.30% |
| 2021-12-31 | Skr439.38 Million ≈ $47.28 Million |
-53.59% |
| 2020-12-31 | Skr946.76 Million ≈ $101.89 Million |
-4.70% |
| 2019-12-31 | Skr993.49 Million ≈ $106.92 Million |
+123.49% |
| 2018-12-31 | Skr444.53 Million ≈ $47.84 Million |
-7.36% |
| 2017-12-31 | Skr479.82 Million ≈ $51.64 Million |
+762.48% |
| 2016-12-31 | Skr55.63 Million ≈ $5.99 Million |
+1163.80% |
| 2015-12-31 | Skr4.40 Million ≈ $473.73K |
-66.46% |
| 2014-12-31 | Skr13.12 Million ≈ $1.41 Million |
-- |
About Oncopeptides AB
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company's PDC platform desig… Read more